NasdaqGS - Nasdaq Real Time Price
USD
Madrigal Pharmaceuticals, Inc. (MDGL)
430.36
-1.34
(-0.31%)
At close: 4:00:01 PM EDT
430.36
0.00
(0.00%)
After hours: 4:00:13 PM EDT
Trade MDGL on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
Amounts are as of December 31, 2025 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. William J. Sibold
|
CEO, President & Director | 2.37M | -- | 1966 |
|
Dr. Rebecca A. Taub M.D.
|
Founder, Senior Scientific & Medical Advisor and Director | 1.22M | -- | 1952 |
|
Ms. Mardi C. Dier
|
Executive VP & CFO | 1.21M | 1.34M | 1964 |
|
Ms. Shannon Kelley
|
Executive VP, Chief Legal Officer & Corporate Secretary | 1.07M | -- | 1975 |
|
Ms. Carole Huntsman
|
Executive VP & Chief Commercial Officer | 1.08M | -- | 1965 |
|
Dr. David Soergel M.D.
|
Executive VP & Chief Medical Officer | 1.08M | -- | 1968 |
|
Mr. Mark Underwood
|
Executive Vice President of Business Planning & Operations | -- | -- | -- |
|
Ms. Rita Thakkar
|
Senior VP & Chief Accounting Officer | -- | -- | 1974 |
|
Mr. Ronald Filippo
|
Executive VP & Chief Information Officer | -- | -- | -- |
|
Ms. Tina E. Ventura
|
Chief Investor Relations Officer | -- | -- | -- |
Madrigal Pharmaceuticals, Inc.
1001 Conshohocken State Road
Suite 2-350
West Conshohocken, PA 19428
United States
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 915
Description
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
Corporate Governance
Madrigal Pharmaceuticals, Inc.’s ISS Governance QualityScore as of October 1, 2026 is 5. The pillar scores are Audit: 2; Board: 3; Shareholder Rights: 8; Compensation: 5.
Corporate governance scores courtesy of
Institutional Shareholder Services (ISS)
Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
November 3, 2026 at 12:30 PM UTC
Madrigal Pharmaceuticals, Inc. Earnings Date
